CD274 and cancer: Seventy-five sesquiterpenoids were tentatively characterized in GD-NAIs, in which four sesquiterpenoids would be the main active ingredients against CML, regulating PD-L1 expression and the PD-1 checkpoint pathway in cancer, PI3K/AKT, JAK/STAT, TGF-β, estrogen, Notch and Wnt signaling pathways.